Skip to main content
Top
Published in: Indian Journal of Gastroenterology 2/2019

01-04-2019 | Hepatitis C | Original Article

Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis

Authors: Balkumar Reddy Panyala, Rathindra Mohan Mukherjee, Himaja Devarakonda, Sivasathish Tadivaka, Nagaraja Rao Padaki, Mithun Sharma, Nageshwar Reddy Duvvuru

Published in: Indian Journal of Gastroenterology | Issue 2/2019

Login to get access

Abstract

Introduction

Hepatitis C virus (HCV) displays high genetic diversity, characterized by regional variations in the prevalence of genotype posing challenges to the development of vaccines and definitive treatment. Very few reports exist on the distribution and frequency change of HCV genotypes in India. In the present retrospective study, we aimed to understand the distribution pattern of HCV genotypes and viral load among HCV-infected patients attending the Asian Institute of Gastroenterology, Hyderabad, India, a tertiary care hospital.

Methods

Patients referred to the Hepatology Department from January 2009 to December 2015 were screened for this study. Eight hundred and sixty-two chronic HCV patients were included in this study. Genotyping was performed using type-specific probe-based hybridization assay and viral load was estimated by real-time polymerase chain reaction.

Results

Out of 862 patients, genotype 1 was detected predominantly in 392 (45.5%), followed by genotype 3 in 344 (39.9%) patients; genotypes 4, 6, and 2 were detected in 115 (13.3%), 8 (0.9%), and 3 (0.3%) patients, respectively. The number of patients having genotype 1 increased in frequency while genotype 3 became less from the year 2009 to 2015. Patients having genotype 1 had significantly (p < 0.0001) higher viral load compared with the patients infected with other genotypes.

Conclusion

Our study results demonstrate a change in HCV genotypic distribution pattern from genotypes 3 to 1 during the span of 7 years in patients referred to our hospital. In the light of the reported difference in the pathogenic potential of various HCV genotypes, detection of HCV genotype appears to be still essential for better patient management.
Literature
2.
go back to reference Cooke GS, Lemoine M, Thursz M, et al. Viral hepatitis and the global burden of disease: a need to regroup. J Viral Hepat. 2013;20:600–1.CrossRefPubMed Cooke GS, Lemoine M, Thursz M, et al. Viral hepatitis and the global burden of disease: a need to regroup. J Viral Hepat. 2013;20:600–1.CrossRefPubMed
3.
go back to reference Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specifc antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRef Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specifc antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRef
4.
go back to reference Khaja MN, Munpally SK, Hussain MM, Habeebullah CM. Hepatitis C virus: the Indian scenario. Curr Sci. 2002;83:219–24. Khaja MN, Munpally SK, Hussain MM, Habeebullah CM. Hepatitis C virus: the Indian scenario. Curr Sci. 2002;83:219–24.
5.
go back to reference Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36:91–133.CrossRefPubMed Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36:91–133.CrossRefPubMed
6.
7.
go back to reference Jane PM, Isla H, Abraham F, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.CrossRef Jane PM, Isla H, Abraham F, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.CrossRef
8.
go back to reference Jacobson IM, Gordon C, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.CrossRefPubMed Jacobson IM, Gordon C, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.CrossRefPubMed
9.
go back to reference Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed
10.
11.
go back to reference Garcia-Montalvo BM, Galguera-Colorado PL. Distribution of hepatitis C virus genotypes, risk factors and liver disease in patients from Yucatan, Mexico. Ann Hepatol. 2008;7:345–9.CrossRefPubMed Garcia-Montalvo BM, Galguera-Colorado PL. Distribution of hepatitis C virus genotypes, risk factors and liver disease in patients from Yucatan, Mexico. Ann Hepatol. 2008;7:345–9.CrossRefPubMed
12.
go back to reference Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from northern India. Diagn Microbiol Infect Dis. 2008;61:408–14.CrossRefPubMed Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from northern India. Diagn Microbiol Infect Dis. 2008;61:408–14.CrossRefPubMed
13.
go back to reference Chakravarti A, Verma V. Distribution of hepatitis genotypes in β-thalassaemic patients from North India. Trans Med. 2006;16:433–8.CrossRef Chakravarti A, Verma V. Distribution of hepatitis genotypes in β-thalassaemic patients from North India. Trans Med. 2006;16:433–8.CrossRef
14.
go back to reference Panigrahi AK, Roca J, Acharya SK, Jameel S, Panda SK. Genotype determination of hepatitis C virus from northern India: identification of new subtypes. J Med Virol. 1996;48:191–8.CrossRefPubMed Panigrahi AK, Roca J, Acharya SK, Jameel S, Panda SK. Genotype determination of hepatitis C virus from northern India: identification of new subtypes. J Med Virol. 1996;48:191–8.CrossRefPubMed
15.
go back to reference Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrisomn TJ. Diversity of genotypes of hepatitis C virus in southern India. J Gen Virol. 1995;76:711–6.CrossRefPubMed Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrisomn TJ. Diversity of genotypes of hepatitis C virus in southern India. J Gen Virol. 1995;76:711–6.CrossRefPubMed
16.
go back to reference Chowdhury A, Santra A, Chaudhuri S, et al. Hepatitis C virus in the general population: a community-based study in West Bengal, India. Hepatology. 2003;37:802–9.CrossRefPubMed Chowdhury A, Santra A, Chaudhuri S, et al. Hepatitis C virus in the general population: a community-based study in West Bengal, India. Hepatology. 2003;37:802–9.CrossRefPubMed
17.
go back to reference Raghuraman S, Shaji RV, Sridharan G, et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. J Clin Virol. 2003;26:61–9.CrossRefPubMed Raghuraman S, Shaji RV, Sridharan G, et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. J Clin Virol. 2003;26:61–9.CrossRefPubMed
18.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.CrossRefPubMed
19.
go back to reference Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.CrossRefPubMed Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.CrossRefPubMed
20.
go back to reference Gupta V, Kumar A, Sharma P, et al. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north Inida. J Clin Exp Hepatol. 2014;4:287–92.CrossRefPubMedPubMedCentral Gupta V, Kumar A, Sharma P, et al. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north Inida. J Clin Exp Hepatol. 2014;4:287–92.CrossRefPubMedPubMedCentral
21.
go back to reference Puri P, Anand AC, Saraswat VA, et al. Consensus statement of HCV task force of the Indian National Association for the Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol. 2014;4:106–16.CrossRefPubMedPubMedCentral Puri P, Anand AC, Saraswat VA, et al. Consensus statement of HCV task force of the Indian National Association for the Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol. 2014;4:106–16.CrossRefPubMedPubMedCentral
22.
go back to reference Mir F, Kahveci AS, Ibdah JA, Tahan V. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017;11:497–502.CrossRefPubMedPubMedCentral Mir F, Kahveci AS, Ibdah JA, Tahan V. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017;11:497–502.CrossRefPubMedPubMedCentral
23.
go back to reference Christdas J, Sivakumar J, David J, Daniel HD, Raghuraman S, Abraham P. Genotypes of hepatitis C virus in the Indian sub-continent: a decade long experience from a tertiary care hospital in South India. Indian J Med Microbiol. 2013;31:349–53.CrossRefPubMed Christdas J, Sivakumar J, David J, Daniel HD, Raghuraman S, Abraham P. Genotypes of hepatitis C virus in the Indian sub-continent: a decade long experience from a tertiary care hospital in South India. Indian J Med Microbiol. 2013;31:349–53.CrossRefPubMed
24.
go back to reference Chowdhury A, Santra A, Chaudhuri S, et al. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology. 2003;37:802–9.CrossRefPubMed Chowdhury A, Santra A, Chaudhuri S, et al. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology. 2003;37:802–9.CrossRefPubMed
25.
go back to reference Kumar JP, Puttamaregowda H. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Karnataka, South India. Int J Adv Med. 2016;3:905–7.CrossRef Kumar JP, Puttamaregowda H. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Karnataka, South India. Int J Adv Med. 2016;3:905–7.CrossRef
26.
go back to reference Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high titer viraemia correlates with advanced stage of disease. J Infect Dis. 1994;169:1219–25.CrossRefPubMed Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high titer viraemia correlates with advanced stage of disease. J Infect Dis. 1994;169:1219–25.CrossRefPubMed
27.
go back to reference Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology. 1993;17:545–50.CrossRefPubMed Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology. 1993;17:545–50.CrossRefPubMed
28.
go back to reference Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes and its association with viral load. Indian J Med Res. 2011;133:326–31.PubMedPubMedCentral Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes and its association with viral load. Indian J Med Res. 2011;133:326–31.PubMedPubMedCentral
29.
go back to reference Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Sarang HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U. S Veterans with HCV. Hepatology. 2014;60:98–105.CrossRefPubMed Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Sarang HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U. S Veterans with HCV. Hepatology. 2014;60:98–105.CrossRefPubMed
30.
go back to reference McMahon BJ, Bruden D, Townshend-Bulson L, et al. Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma and liver-related death. Clin Gastroenterol Hepatol. 2017;15:431–7.CrossRefPubMed McMahon BJ, Bruden D, Townshend-Bulson L, et al. Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma and liver-related death. Clin Gastroenterol Hepatol. 2017;15:431–7.CrossRefPubMed
Metadata
Title
Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis
Authors
Balkumar Reddy Panyala
Rathindra Mohan Mukherjee
Himaja Devarakonda
Sivasathish Tadivaka
Nagaraja Rao Padaki
Mithun Sharma
Nageshwar Reddy Duvvuru
Publication date
01-04-2019
Publisher
Springer India
Keyword
Hepatitis C
Published in
Indian Journal of Gastroenterology / Issue 2/2019
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-019-00934-x

Other articles of this Issue 2/2019

Indian Journal of Gastroenterology 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.